Phase 1
N=122
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
Hepatitis B
Bottom Line
View on ClinicalTrials.gov: NCT05561673 ↗Enrolled (actual)
122
Serious AEs
0.8%
Results posted
Jan 2026
Primary outcome: Primary: Number of Participants With Solicited Administration Site Adverse Events (AEs) After Dose 1 — 0; 0; 0; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide (Combination_product); GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system (Biological); GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system (Biological); GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37B adjuvant system (50 μg) (Biological); GSK's HBsAg (20 μg) vaccine adjuvanted with GSK's AS37A adjuvant system (100 μg) (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Solicited Administration Site Adverse Events (AEs) After Dose 1 |
0; 0; 0; 0; 0; 6 | — |
| PRIMARY Number of Participants With Solicited Administration Site AEs After Dose 2 |
0; 0; 0; 0; 0; 1 | — |
| PRIMARY Number of Participants With Solicited Systemic AEs After Dose 1 |
1; 2; 2; 2; 1; 2 | — |
| PRIMARY Number of Participants With Solicited Systemic AEs After Dose 2 |
2; 3; 1; 1; 1; 2 | — |
| PRIMARY Duration in Days of Solicited Administration Site AEs After Dose 1 |
1.0; 1.0; 3.0; 2.0; 1.0 | — |
| PRIMARY Duration in Days of Solicited Administration Site AEs After Dose 2 |
1.0; 2.0; 4.0; 1.5; 2.0 | — |
| PRIMARY Duration in Days of Solicited Systemic AEs After Dose 1 |
2.0; 1.5; 1.0; 2.0; 1.0; 1.5 | — |
| PRIMARY Duration in Days of Solicited Systemic AEs After Dose 2 |
2.0; 1.0; 1.0; 5.0; 1.0; 1.0 | — |
| PRIMARY Number of Participants With Any Unsolicited AEs After Dose 1 |
7; 2; 6; 4; 5 | — |
| PRIMARY Number of Participants With Any Unsolicited AEs After Dose 2 |
5; 7; 6; 6; 6 | — |
| PRIMARY Number of Participants With Serious AEs (SAEs) |
0; 0; 0; 1; 0 | — |
| PRIMARY Number of Participants With Medically Attended AEs (MAEs) |
8; 2; 2; 3; 4 | — |
| PRIMARY Number of Participants With AEs Leading to Study Withdrawal |
0; 0; 0; 0; 0 | — |
| PRIMARY Number of Participants With Potential Mediated Immune Diseases (pIMDs) |
0; 0; 0; 1; 0 | — |
| PRIMARY Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 1 |
-2.45; 12.52; 2.94; 5.89; 3.07; -0.60 | — |
| PRIMARY Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 1 |
-2.45; 12.52; 2.94; 5.89; 3.07; -0.60 | — |
| PRIMARY Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 2 |
-4.71; 61.39; 12.94; 4.67; 13.83; 8.19 | — |
| PRIMARY Mean Percent Change From Baseline (Pre-vaccination, Day 1) in Hematology and Biochemistry Parameters Post-dose 2 |
-4.71; 61.39; 12.94; 4.67; 13.83; 8.19 | — |
| PRIMARY Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 1 |
0; 0; 0; 0; 0; 21 | — |
| PRIMARY Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 8 |
0; 0; 0; 0; 0; 23 | — |
| PRIMARY Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 31 |
0; 0; 0; 0; 0; 19 | — |
| PRIMARY Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 38 |
0; 0; 0; 0; 0; 19 | — |
| PRIMARY Number of Participants With Abnormal Hematology and Biochemistry Laboratory Parameter Values at Day 61 |
0; 0; 0; 0; 0; 21 | — |
| SECONDARY Geometric Mean Concentration (GMC) of Anti-HBs Antibody Concentrations |
3.4; 3.1; 3.1; 3.1; 3.1; 7.7 | — |
| SECONDARY Percentage of Participants Who Seroconverted for Anti-HBs |
16.7; 95.5; 21.7; 59.1; 81.0; 75.0 | — |
| SECONDARY Percentage of Participants Seroprotected for Anti-HBs |
16.7; 95.5; 21.7; 59.1; 81.0; 62.5 | — |
Summary
This study is conducted to assess safety and immunogenicity of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system in healthy, HBs naïve, adults aged 18-45 years and to differentiate GSK's AS37 adjuvant system from other approved adjuvant systems and from an aluminum-based adjuvant.
Eligibility Criteria
Inclusion Criteria
- Participants who the investigator believe can and will comply with the requirements of the protocol.
- Written informed consent obtained from the participant prior to performance of any study-specific procedure.
- Healthy participants as established by medical history, clinical examination and clinical laboratory assessment before entering the study.
- A male or female between, and including, 18 and 45 years at the time of the first study intervention administration.
- Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
- Female participants of childbearing potential may be enrolled in the study, if the participant:
- has practiced adequate contraception for 1 month prior to study intervention administration, and
- has a negative pregnancy test on the day of study intervention administration, and
- has agreed to continue adequate contraception during the entire treatment period and for at least 3 months after completion of the study intervention administration series.
- blood sample for simultaneous follicle-stimulating hormone (FSH) and estradiol levels may be collected at the discretion of the investigator to confirm non-reproductive potential according to local laboratory reference range.
Exclusion Criteria
Medical conditions
- Previous vaccination against Hepatitis B.
- Positive for anti-HBs antibodies or anti-HBc antibodies or HBsAg.
- Any previous administration of monophosphoryl lipid (MPL) and/or AS37.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Any confirmed or suspected autoimmune disease.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
- Recurrent history or uncontrolled neurological disorders or seizures.
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- Any clinically significant* haematological and/or biochemical laboratory abnormality.
*The investigator should use his/her clinical judgement to decide which abnormalities are clinically significant.
- Any past or current malignancies and lymphoproliferative disorders.
Prior/Concomitant therapy
- Use of any investigational or non-registered product (drug or vaccine) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) or their planned use during the study period.
- Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study intervention(s) administration with the exception of influenza vaccine (pandemic or seasonal).
- A vaccine not foreseen by the study protocol administered during the period starting at Visit 1 or 30 days before each dose and ending 30 days after the last dose of study intervention(s) administration*, with the exception of influenza vaccine (pandemic or seasonal).
*In case emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is organised by public health authorities outside the routine immunisation programme, the time period described above can be reduced if necessary for that vaccine, provided it is licensed/authorised and used according to its Product Information.
- Administration of long-acting immune-modifying drugs at any time during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months before the first study intervention dose(s). For corticosteroids, this will mean prednisone equivalent ≥ 20 mg/day. Inhaled and topical steroids are allowed.
*
Data sourced from ClinicalTrials.gov (NCT05561673). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.